<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31771">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01892618</url>
  </required_header>
  <id_info>
    <org_study_id>2009-012642-22</org_study_id>
    <nct_id>NCT01892618</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccine in Untreated CLL Patients</brief_title>
  <official_title>A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether patients with chronic lymphocytic leukaemia
      (CLL) will benefit from vaccination with a 13-valent conjugated pneumococcal vaccine,
      Prevenar13, compared with a conventional 23-valent capsular polysaccharide vaccine in terms
      of immune response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Immune response to Pneumovax compared to immune response to Prevenar</measure>
    <time_frame>1 month post vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific immunoglobulin G (IgG) antibody levels</measure>
    <time_frame>1 and 6 months post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immune response to Pneumovax vs. Prevenar13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of opsonophagocytic antibodies (OPA)</measure>
    <time_frame>6 months post vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immune response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific IgG antibody levels by ELISA, geometric mean concentrations (GMCs)between arms</measure>
    <time_frame>1 and 6 months post vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Pneumovax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pneumovax, 1x 0.5 ml injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prevenar 13, 1x 0.5 ml injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>13-valent pneumococcal conjugated vaccine</description>
    <arm_group_label>Prevenar 13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pneumovax</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine</description>
    <arm_group_label>Pneumovax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Untreated CLL patients all Rai stages (0 to IV), as early as possible after
             diagnosis, always before any therapy with monoclonal antibodies and/or chemotherapy

        Exclusion Criteria:

          -  Immunosuppressive therapy planned to start within 1 month

          -  Other malignancies

          -  Corticosteroids or other immunosuppressive drugs

          -  Previous allergic reaction to any vaccination in the past

          -  Neutropenia (PMNs &lt; 500 cells/mm3)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Kimby, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital, SE-141 86 Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Kimby, Professor</last_name>
    <phone>+46 708540188</phone>
    <email>eva@kimby.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tobias Svensson, MD</last_name>
    <phone>+46 705141539</phone>
    <email>tobsvensson@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Kimby, Professor</last_name>
      <phone>+46 70854 01 88</phone>
      <email>eva@kimby.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>June 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Eva Kimby</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
